Skip to main content

DeAnna J. Friedman-Klabanoff, MD

Academic Title:


Primary Appointment:



685 W. Baltimore St.

Phone (Primary):




Education and Training

University of Wisconsin-Madison, B.S., Medical Microbiology and Immunology, 2004

University of Wisconsin School of Medicine and Public Health, M.D., 2009

Residency, University of Minnesota, Pediatrics, 2012

Fellowship, University of Maryland School of Medicine, Pediatric Infectious Diseases, 2019


Dr. Friedman-Klabanoff is a board-certified pediatric infectious disease specialist with a primary research interest in malaria vaccine development and natural and vaccine-induced immunity to Plasmodium falciparum, the most common and deadly cause of malaria worldwide. She is helping to lead a Phase I trial of a new malaria vaccine candidate based on the full-length circumsporozoite protein, examining the safety, immunogenicity and preliminary efficacy against controlled human malaria infection. Leveraging samples from this trial, Dr. Friedman-Klabanoff will examine the humoral immune responses to this vaccine on a peptide microarray to determine if those protected from infection have different antibody responses to the vaccine than those who are not. She is utilizing the peptide array platform to examine natural immunity to the pre-erythrocytic stages of malaria and protection from infection in a cohort of children in Malawi, supported by the Burroughs-Wellcome/ASTMH Postdoctoral Fellowship under the mentorship of Dr. Miriam Laufer. The overall goal of these projects is to examine the fine specificity of pre-erythrocytic antibodies to refine future malaria vaccine efforts. Her recently funded K23 will expand upon this work and incorporate in vitro functional assays to test potential novel malaria vaccine candidates. 

Recently, Dr. Friedman-Klabanoff has expanded her research to also study the use of serological assays to track the spread of SARS-CoV-2 in the community through the COVID-19 Community Research Partnership. She also conducts vaccine trials for malaria, mosquito-borne diseases, and SARS-CoV-2. 

Research/Clinical Keywords

Malaria, malaria vaccine development, humoral immunity, SARS-CoV-2 serology, clinical vaccine trials, peptide microarray, human challenge studies, controlled human infection

Highlighted Publications

Friedman-Klabanoff DJ, Berry AA, Travassos MA, Cox C, Zhou Y, Mo AX, Nomicos EYH, Deye GA, Pasetti MF, Laurens MB. Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in Phase 1 first-in-human clinical testing. 2021 Feb 22, 39(8): 1195-1200. doi: 10.1016/j.vaccine.2020.12.023. Epub 2021 Jan 22. PMID: 33494963.

Friedman-Klabanoff DJ, Travassos MA, Ifeonu OO, Agrawal S, Ouattara A, Pike A, Bailey JA, Adams M, Coulibaly D, Lyke KE, Laurens MB, Takala-Harrison S, Kouriba B, Kone AK, Doumbo OK, Patel JJ, Thera MA, Felgner PL, Tan JC, Plowe CV, Berry AA. Epitope-specific antibody responses to a Plasmodium falciparum subunit vaccine target in a malaria-endemic population. J Infect Dis. 2020 Sep 29:jiaa611. doi: 10.1093/infdis/jiaa611. Online ahead of print.

Friedman-Klabanoff DJ, Laurens MB, Berry AA, Travassos MA, Adams M, Strauss KA, Shrestha B, Levine MM, Edelman R, Lyke KE. The controlled human malaria infection experience at the University of Maryland. Am J Trop Med Hyg. 2019; 100(3): 556-565.

Additional Publication Citations


Friedman-Klabanoff DJ, Campbell JD. A 29-day-old Infant with Poor Feeding and a Rash. Pediatr Rev. 2021 Jan;42(Suppl 1):S15-S18. doi: 10.1542/pir.2019-0096.



Clinical Specialty Details

Dr. Friedman-Klabanoff is a board-certified pediatric infectious disease specialist. She attends on the pediatric infectious disease consult service, on which she also teaches medical students, residents, and fellows. 

Awards and Affiliations

2018 – 2020  National Institutes of Health Loan Repayment Program

2019 – 2021  Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases

2019 – 2021  Pichichero Family Foundation Research Development, Vaccines for Children Initiative Award in Pediatric Infectious Diseases

2021 - 2023  Passano Foundation Clinician-Investigator Award for Career Development

Grants and Contracts

Dr. Friedman-Klabanoff works on numerous contracts; a select number are included below. Please refer to her CV for a full listing.

DeAnna Friedman-Klabanoff, M.D. (PI)
2021 – present
Serological markers of natural immunity to Plasmodium falciparum infection
Wilbur Chen, M.D. (PI)
Role: Co-Investigator
2020 – present
Centers for Disease Control and Prevention/Subaward from Vysnova Partners, Inc.
Applied Research to Address the COVID-19 Emerging Public Health Emergency
Matthew Laurens, M.D. (PI)
Role: Sub-Investigator
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older
DeAnna Friedman-Klabanoff, M.D. (PI)
2019 – present
Burroughs-Wellcome Fund/American Society of Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases
In search of natural immunity: finding serologic markers of immunity after exposure to malaria
DeAnna Friedman-Klabanoff, M.D. (PI)
2019 – present
Pichichero Family Foundation Vaccines for Children Initiative Research Award in Pediatric Infectious Diseases
A novel, translational approach to malaria vaccine development
Matthew Laurens, M.D. (PI)
Role: Co-Investigator
2017 – present
A Phase 1 Challenge Study to Evaluate Safety, Immunogenicity and Efficacy of a Malaria Vaccine (rCSP adjuvanted with GLA-LSQ), in Healthy Adults, DMID 13-0088
Andrea Berry, M.D. (PI)
Role: Co-Investigator
2017 – present
A sub-study to evaluate epitope mapping of antibodies elicited by controlled human malaria infection, vaccination, and natural infection with Plasmodium falciparum malaria in 14-0040, 15-0052, and 13-0088